This is a news story, published by Ars Technica, that relates primarily to FDA news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
tirzepatide drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest prescriptions news, drug shortage list news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
tirzepatide shortageArs Technica
•
81% Informative
Compounding pharmacies are suing the FDA to keep making imitation versions of popular GLP-1 drugs.
Tirzepatide has been in short supply in recent years .
The FDA announced last week that the shortage had been resolved and that the nation's supply is stabilizing.
VR Score
78
Informative language
75
Neutral language
61
Article tone
formal
Language
English
Language complexity
67
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
2
Affiliate links
no affiliate links